Verici Dx is developing blood-based diagnostic tests designed to improve risk assessment in kidney transplant care. Its clinical data focus on RNA signatures that may help identify risks linked to kidney injury, acute rejection, fibrosis and graft loss.
The company’s approach is built around the idea that transplant outcomes are influenced by complex biological pathways. Instead of relying on a single marker, Verici Dx analyses gene expression across the full transcriptome. It then uses algorithms and machine learning to turn those signals into risk scores that can support clinical decision-making.
Kidney transplant monitoring is time-sensitive. Acute rejection and other forms of graft injury can develop before clear clinical signs appear. A test that helps stratify risk from a blood sample could have practical value in identifying which patients may need closer review, further testing or intervention.
Verici Dx has supported its portfolio with a global observational clinical study. The study targeted enrolment of 550 patients across 16 centres in six countries and was designed to validate Tutivia, Clarava and Protega. The multicentre design is important because transplant practice differs between hospitals and patient populations. Broader participation helps test whether the diagnostic approach is relevant across real clinical settings.
Tutivia has also been studied in a prospective, multicentre, blinded international trial with 13 contributing transplant sites. The study included adult kidney transplant recipients aged 18 to 80, including recipients of living or deceased donor kidneys. It also included high-risk donor organs and patients with class 1 or class 2 donor-specific antibodies, where informed consent was obtained.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
